These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 1782724

  • 1. Oral iron absorption in hemodialysis patients treated with erythropoietin.
    Donnelly SM, Posen GA, Ali MA.
    Clin Invest Med; 1991 Aug; 14(4):271-6. PubMed ID: 1782724
    [Abstract] [Full Text] [Related]

  • 2. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N, Osman-Malik Y, Frinak S, Besarab A.
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [Abstract] [Full Text] [Related]

  • 3. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
    Silverberg DS, Blum M, Agbaria Z, Deutsch V, Irony M, Schwartz D, Baruch R, Yachnin T, Steinbruch S, Iaina A.
    Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
    [Abstract] [Full Text] [Related]

  • 4. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H, Wang SX.
    Blood Purif; 2008 Mar; 26(2):151-6. PubMed ID: 18212498
    [Abstract] [Full Text] [Related]

  • 5. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin.
    Markowitz GS, Kahn GA, Feingold RE, Coco M, Lynn RI.
    Clin Nephrol; 1997 Jul; 48(1):34-40. PubMed ID: 9247776
    [Abstract] [Full Text] [Related]

  • 6. Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythropoietin (EPO).
    Saltissi D, Sauvage D, Westhuyzen J.
    Clin Nephrol; 1998 Jan; 49(1):45-8. PubMed ID: 9491286
    [Abstract] [Full Text] [Related]

  • 7. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F, David S, Sala P, Icardi A, Casani A.
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [Abstract] [Full Text] [Related]

  • 8. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
    Chen YC, Hung SC, Tarng DC.
    Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
    [Abstract] [Full Text] [Related]

  • 9. [Can anemia be corrected in hemodialysis patients with thalassaemia minor? ].
    Di Iorio B, Guastaferro P, Gironda A, Marano V, Morrongiello L, Cillo N, Zito B, Nigro F, Frieri A, Rubino R, Bellizzi V.
    G Ital Nefrol; 2002 Jun; 19(5):552-9. PubMed ID: 12439845
    [Abstract] [Full Text] [Related]

  • 10. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
    Coronel F, Herrero JA, Montenegro J, Fernandez C, Gandara A, Conesa J, Rivera MT, Torrente J, Portolés J, Gomez-Martino JR.
    J Nephrol; 2003 Jun; 16(5):697-702. PubMed ID: 14733416
    [Abstract] [Full Text] [Related]

  • 11. [Treatment of anemia with recombinant human erythropoietin and the bone marrow response in uremic patients undergoing periodic hemodialysis].
    García Martín F, Carrascosa Vallejo T, Martín Escobar E, Val Begueria J, Martín Hernández R, de Arriba G, Teno C, Salvatierra J.
    Rev Clin Esp; 1990 May; 186(9):419-22. PubMed ID: 2247677
    [Abstract] [Full Text] [Related]

  • 12. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].
    Canaud B, Polito-Bouloux C, Rivory JP, Donnadieu P, Taib J, Florence P, Mion C.
    Nephrologie; 1990 May; 11(1):5-10. PubMed ID: 2374643
    [Abstract] [Full Text] [Related]

  • 13. Lymphocyte 5'-nucleotidase and aminopeptidase N activity in patients on maintenance hemodialysis treated with human recombinant erythropoietin and 1-alpha-D3.
    Stefanovic V, Mitić-Zlatkovic M, Radivojevic J, Vlahovic P.
    Ren Fail; 2005 May; 27(3):283-8. PubMed ID: 15957544
    [Abstract] [Full Text] [Related]

  • 14. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
    El-Khatib M, Duncan HJ, Kant KS.
    Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
    [Abstract] [Full Text] [Related]

  • 15. Effects of erythropoietin therapy on iron absorption in chronic renal failure.
    Skikne BS, Ahluwalia N, Fergusson B, Chonko A, Cook JD.
    J Lab Clin Med; 2000 Jun; 135(6):452-8. PubMed ID: 10850644
    [Abstract] [Full Text] [Related]

  • 16. [Influence of iron metabolism on the efficacy of r-HuEPO (recombinant human erythropoietin) treatment of anemia in children on hemodialysis].
    Pela I, Lavoratti GC, Materassi M, Burgio G, Bartolozzi G.
    Pediatr Med Chir; 1991 Jun; 13(5):475-7. PubMed ID: 1788107
    [Abstract] [Full Text] [Related]

  • 17. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients.
    Drüeke TB, Bárány P, Cazzola M, Eschbach JW, Grützmacher P, Kaltwasser JP, Macdougall IC, Pippard MJ, Shaldon S, van Wyck D.
    Clin Nephrol; 1997 Jul; 48(1):1-8. PubMed ID: 9247771
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effect of hepatitis C infection on anemia in hemodialysis patients.
    Khurana A, Nickel AE, Narayanan M, Foulks CJ.
    Hemodial Int; 2008 Jan; 12(1):94-9. PubMed ID: 18271849
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.